Keigo Araki

1.4k total citations · 1 hit paper
24 papers, 1.1k citations indexed

About

Keigo Araki is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Keigo Araki has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Keigo Araki's work include Cancer-related Molecular Pathways (15 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Epigenetics and DNA Methylation (4 papers). Keigo Araki is often cited by papers focused on Cancer-related Molecular Pathways (15 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Epigenetics and DNA Methylation (4 papers). Keigo Araki collaborates with scholars based in Japan, United States and Singapore. Keigo Araki's co-authors include Keiko Kawauchi, Nobuyuki Tanaka, Kei Tobiume, Masa‐Aki Ikeda, Yusuke Nakajima, Kazuhiro Eto, Kiyoshi Ohtani, Hiroaki Hirata, Takahiro Ebata and Yasuhiro Sawada and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Cell Biology and Journal of Molecular Biology.

In The Last Decade

Keigo Araki

24 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation

2008 539 citations Keiko Kawauchi, Keigo Araki et al. Nature Cell Biology profile →

Peers

Keigo Araki

ONCOL

IMMUN

Daniele Lecis Italy

Wendy W. Hwang‐Verslues Taiwan

Lauretta Levati Italy

Luciana P. Schwab United States

Nobuhiro Tanuma Japan

Katherine Drews‐Elger United States

Ju‐Ming Wang Taiwan

Krasil'nikov Ma Russia

Daniel T. Dransfield United States

Lingtao Jin United States

Daniele Lecis Italy

Keigo Araki

862 ×1.1

203 ×0.4

310 ×0.8

ONCOL

203 ×1.0

IMMUN

90 ×0.9

Citations per year, relative to Keigo Araki Keigo Araki (= 1×) peers Daniele Lecis

Countries citing papers authored by Keigo Araki

Since Specialization

Citations

This map shows the geographic impact of Keigo Araki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keigo Araki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keigo Araki more than expected).

Fields of papers citing papers by Keigo Araki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keigo Araki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keigo Araki. The network helps show where Keigo Araki may publish in the future.

Co-authorship network of co-authors of Keigo Araki

This figure shows the co-authorship network connecting the top 25 collaborators of Keigo Araki. A scholar is included among the top collaborators of Keigo Araki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keigo Araki. Keigo Araki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iwanaga, Ritsuko, et al.. (2025). Transcriptional Activation Mechanisms and Target Genes of the Oncogene Product Tax of Human T-Cell Leukemia Virus Type 1. Genes. 16(10). 1221–1221. 1 indexed citations

Araki, Keigo, et al.. (2024). Non-canonical olfactory pathway activation induces cell fusion of cervical cancer cells. Neoplasia. 57. 101044–101044. 1 indexed citations

Kamiya, Yuki, Ritsuko Iwanaga, Andrew P. Bradford, et al.. (2024). DEAD/H Box 5 (DDX5) Augments E2F1-Induced Cell Death Independent of the Tumor Suppressor p53. International Journal of Molecular Sciences. 25(24). 13251–13251. 1 indexed citations

Hayati, Rahma, et al.. (2024). Trans-Activation of the Coactivator-Associated Arginine Methyltransferase 1 (Carm1) Gene by the Oncogene Product Tax of Human T-Cell Leukemia Virus Type 1. Genes. 15(6). 698–698. 2 indexed citations

Iwanaga, Ritsuko, et al.. (2024). Activation of the CDK7 Gene, Coding for the Catalytic Subunit of the Cyclin-Dependent Kinase (CDK)-Activating Kinase (CAK) and General Transcription Factor II H, by the Trans-Activator Protein Tax of Human T-Cell Leukemia Virus Type-1. Genes. 15(8). 1080–1080. 2 indexed citations

Iwanaga, Ritsuko, et al.. (2023). Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool. Genes. 14(2). 393–393. 12 indexed citations

Komori, Hideyuki, et al.. (2023). The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochemical and Biophysical Research Communications. 663. 154–162. 9 indexed citations

Iwanaga, Ritsuko, et al.. (2023). Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression. Biology. 12(12). 1511–1511. 17 indexed citations

Komori, Hideyuki, Eiko Ozono, Ritsuko Iwanaga, et al.. (2018). Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes. Scientific Reports. 8(1). 8438–8438. 12 indexed citations

10.

Araki, Keigo, et al.. (2018). Mitochondrial protein E2F3d, a distinctive E2F3 product, mediates hypoxia-induced mitophagy in cancer cells. Communications Biology. 2(1). 3–3. 20 indexed citations

11.

Okuda, Masahiko, Keigo Araki, Kiyoshi Ohtani, & Yoshifumi Nishimura. (2016). The Interaction Mode of the Acidic Region of the Cell Cycle Transcription Factor DP1 with TFIIH. Journal of Molecular Biology. 428(24). 4993–5006. 10 indexed citations

12.

Ozono, Eiko, et al.. (2016). Ectopic expression of the CDK inhibitor p21 Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter. Biochemical and Biophysical Research Communications. 483(1). 107–114. 4 indexed citations

13.

Araki, Keigo, et al.. (2015). p53 regulates cytoskeleton remodeling to suppress tumor progression. Cellular and Molecular Life Sciences. 72(21). 4077–4094. 32 indexed citations

14.

Kawauchi, Keiko, Keigo Araki, Kei Tobiume, & Nobuyuki Tanaka. (2009). Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification. Proceedings of the National Academy of Sciences. 106(9). 3431–3436. 167 indexed citations

15.

Kawauchi, Keiko, Keigo Araki, Kei Tobiume, & Nobuyuki Tanaka. (2008). Activated p53 induces NF-κB DNA binding but suppresses its transcriptional activation. Biochemical and Biophysical Research Communications. 372(1). 137–141. 58 indexed citations

16.

Kawauchi, Keiko, Keigo Araki, Kei Tobiume, & Nobuyuki Tanaka. (2008). p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nature Cell Biology. 10(5). 611–618. 539 indexed citations breakdown →

17.

Araki, Keigo, Keiko Kawauchi, & Nobuyuki Tanaka. (2008). IKK/NF-κB signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors. Oncogene. 27(43). 5696–5705. 35 indexed citations

18.

Kase, Satoru, Mitsuhiko Osaki, Soichiro Honjo, et al.. (2004). A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.. PubMed. 23(2). 301–7. 16 indexed citations

19.

Araki, Keigo, Yusuke Nakajima, Kazuhiro Eto, & Masa‐Aki Ikeda. (2003). Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter. Oncogene. 22(48). 7632–7641. 59 indexed citations

20.

Ma, Kaiwen, Keigo Araki, Solachuddin Jauhari Arief Ichwan, et al.. (2003). E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53.. PubMed. 1(6). 438–44. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact